ARCHIVES

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

Duke Officials Decline To Provide Details Of Probe

July 23, 2010

In Brief: Progress Reported In NCI-FDA Fight Over New Drug Tests, Epidemiology Branch Reorganized

December 12, 1975

Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34%

June 28, 2013

Clinical Trials Approved By NCI CTEP Last Month

September 30, 2011

Funding Opportunities Listed (12-page issue).

July 11, 2003

New Concepts Being Developed By Organ Systems Groups Described

January 2, 1987